Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis

Virgilo A. Salvo, Stephen M. Boué, Juan P. Fonseca, Steven Elliott, Cynthia Corbitt, Bridgette M. Collins-Burow, Tyler J Curiel, Sudesh K. Srivastav, Betty Y. Shih, Carol Carter-Wientjes, Charles E. Wood, Paul W. Erhardt, Barbara S. Beckman, John A. McLachlan, Thomas E. Cleveland, Matthew E. Burow

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Purpose: We have identified the phytoalexin compounds glyceollins I, II, and III, which exhibit marked antiestrogenic effects on estrogen receptor function and estrogen-dependent tumor growth in vivo. The purpose of this study was to investigate the interactions among the induced soy phytoalexins glyceollins I, II. and III on the growth of estrogen-dependent MCF-7 breast cancer and BG-1 ovarian cancer cells implanted in ovariectomized athymic mice. Experimental Design: Four treatment groups for each cell line were used: vehicle control, 20 mg/kg/mouse/d glyceollin mixture injection, 0.72 mg estradiol (E2) implant, and E2 implant + 20 mg/kg/mouse/d glyceollin injection. Results: Treatment with glyceollin suppressed E2-stimulated tumor growth of MCF-7 cells (-53.4%) and BG-1 cells (-73.1%) in ovariectomized athymic mice. These tumor-inhibiting effects corresponded with significantly lower E2-induced progesterone receptor expression in the tumors. In contrast to tamoxifen, the glyceollins had no estrogen-agonist effects on uterine morphology and partially antagonized the uterotropic effects of estrogen. Conclusions: These findings identify glyceollins as antiestrogenic agents that may be useful in the prevention or treatment of breast and ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)7159-7164
Number of pages6
JournalClinical Cancer Research
Volume12
Issue number23
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Carcinogenesis
Breast Neoplasms
Estrogens
Nude Mice
Neoplasms
Growth
Injections
MCF-7 Cells
Progesterone Receptors
Tamoxifen
glyceollin
Estrogen Receptors
Ovarian Neoplasms
Estradiol
Research Design
Therapeutics
Cell Line
glyceollin II
phytoalexins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Salvo, V. A., Boué, S. M., Fonseca, J. P., Elliott, S., Corbitt, C., Collins-Burow, B. M., ... Burow, M. E. (2006). Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clinical Cancer Research, 12(23), 7159-7164. https://doi.org/10.1158/1078-0432.CCR-06-1426

Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. / Salvo, Virgilo A.; Boué, Stephen M.; Fonseca, Juan P.; Elliott, Steven; Corbitt, Cynthia; Collins-Burow, Bridgette M.; Curiel, Tyler J; Srivastav, Sudesh K.; Shih, Betty Y.; Carter-Wientjes, Carol; Wood, Charles E.; Erhardt, Paul W.; Beckman, Barbara S.; McLachlan, John A.; Cleveland, Thomas E.; Burow, Matthew E.

In: Clinical Cancer Research, Vol. 12, No. 23, 01.12.2006, p. 7159-7164.

Research output: Contribution to journalArticle

Salvo, VA, Boué, SM, Fonseca, JP, Elliott, S, Corbitt, C, Collins-Burow, BM, Curiel, TJ, Srivastav, SK, Shih, BY, Carter-Wientjes, C, Wood, CE, Erhardt, PW, Beckman, BS, McLachlan, JA, Cleveland, TE & Burow, ME 2006, 'Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis', Clinical Cancer Research, vol. 12, no. 23, pp. 7159-7164. https://doi.org/10.1158/1078-0432.CCR-06-1426
Salvo VA, Boué SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM et al. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clinical Cancer Research. 2006 Dec 1;12(23):7159-7164. https://doi.org/10.1158/1078-0432.CCR-06-1426
Salvo, Virgilo A. ; Boué, Stephen M. ; Fonseca, Juan P. ; Elliott, Steven ; Corbitt, Cynthia ; Collins-Burow, Bridgette M. ; Curiel, Tyler J ; Srivastav, Sudesh K. ; Shih, Betty Y. ; Carter-Wientjes, Carol ; Wood, Charles E. ; Erhardt, Paul W. ; Beckman, Barbara S. ; McLachlan, John A. ; Cleveland, Thomas E. ; Burow, Matthew E. / Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. In: Clinical Cancer Research. 2006 ; Vol. 12, No. 23. pp. 7159-7164.
@article{0d8cad2395fd4cdcad5c4fa5e71e97fb,
title = "Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis",
abstract = "Purpose: We have identified the phytoalexin compounds glyceollins I, II, and III, which exhibit marked antiestrogenic effects on estrogen receptor function and estrogen-dependent tumor growth in vivo. The purpose of this study was to investigate the interactions among the induced soy phytoalexins glyceollins I, II. and III on the growth of estrogen-dependent MCF-7 breast cancer and BG-1 ovarian cancer cells implanted in ovariectomized athymic mice. Experimental Design: Four treatment groups for each cell line were used: vehicle control, 20 mg/kg/mouse/d glyceollin mixture injection, 0.72 mg estradiol (E2) implant, and E2 implant + 20 mg/kg/mouse/d glyceollin injection. Results: Treatment with glyceollin suppressed E2-stimulated tumor growth of MCF-7 cells (-53.4{\%}) and BG-1 cells (-73.1{\%}) in ovariectomized athymic mice. These tumor-inhibiting effects corresponded with significantly lower E2-induced progesterone receptor expression in the tumors. In contrast to tamoxifen, the glyceollins had no estrogen-agonist effects on uterine morphology and partially antagonized the uterotropic effects of estrogen. Conclusions: These findings identify glyceollins as antiestrogenic agents that may be useful in the prevention or treatment of breast and ovarian carcinoma.",
author = "Salvo, {Virgilo A.} and Bou{\'e}, {Stephen M.} and Fonseca, {Juan P.} and Steven Elliott and Cynthia Corbitt and Collins-Burow, {Bridgette M.} and Curiel, {Tyler J} and Srivastav, {Sudesh K.} and Shih, {Betty Y.} and Carol Carter-Wientjes and Wood, {Charles E.} and Erhardt, {Paul W.} and Beckman, {Barbara S.} and McLachlan, {John A.} and Cleveland, {Thomas E.} and Burow, {Matthew E.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-06-1426",
language = "English (US)",
volume = "12",
pages = "7159--7164",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis

AU - Salvo, Virgilo A.

AU - Boué, Stephen M.

AU - Fonseca, Juan P.

AU - Elliott, Steven

AU - Corbitt, Cynthia

AU - Collins-Burow, Bridgette M.

AU - Curiel, Tyler J

AU - Srivastav, Sudesh K.

AU - Shih, Betty Y.

AU - Carter-Wientjes, Carol

AU - Wood, Charles E.

AU - Erhardt, Paul W.

AU - Beckman, Barbara S.

AU - McLachlan, John A.

AU - Cleveland, Thomas E.

AU - Burow, Matthew E.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Purpose: We have identified the phytoalexin compounds glyceollins I, II, and III, which exhibit marked antiestrogenic effects on estrogen receptor function and estrogen-dependent tumor growth in vivo. The purpose of this study was to investigate the interactions among the induced soy phytoalexins glyceollins I, II. and III on the growth of estrogen-dependent MCF-7 breast cancer and BG-1 ovarian cancer cells implanted in ovariectomized athymic mice. Experimental Design: Four treatment groups for each cell line were used: vehicle control, 20 mg/kg/mouse/d glyceollin mixture injection, 0.72 mg estradiol (E2) implant, and E2 implant + 20 mg/kg/mouse/d glyceollin injection. Results: Treatment with glyceollin suppressed E2-stimulated tumor growth of MCF-7 cells (-53.4%) and BG-1 cells (-73.1%) in ovariectomized athymic mice. These tumor-inhibiting effects corresponded with significantly lower E2-induced progesterone receptor expression in the tumors. In contrast to tamoxifen, the glyceollins had no estrogen-agonist effects on uterine morphology and partially antagonized the uterotropic effects of estrogen. Conclusions: These findings identify glyceollins as antiestrogenic agents that may be useful in the prevention or treatment of breast and ovarian carcinoma.

AB - Purpose: We have identified the phytoalexin compounds glyceollins I, II, and III, which exhibit marked antiestrogenic effects on estrogen receptor function and estrogen-dependent tumor growth in vivo. The purpose of this study was to investigate the interactions among the induced soy phytoalexins glyceollins I, II. and III on the growth of estrogen-dependent MCF-7 breast cancer and BG-1 ovarian cancer cells implanted in ovariectomized athymic mice. Experimental Design: Four treatment groups for each cell line were used: vehicle control, 20 mg/kg/mouse/d glyceollin mixture injection, 0.72 mg estradiol (E2) implant, and E2 implant + 20 mg/kg/mouse/d glyceollin injection. Results: Treatment with glyceollin suppressed E2-stimulated tumor growth of MCF-7 cells (-53.4%) and BG-1 cells (-73.1%) in ovariectomized athymic mice. These tumor-inhibiting effects corresponded with significantly lower E2-induced progesterone receptor expression in the tumors. In contrast to tamoxifen, the glyceollins had no estrogen-agonist effects on uterine morphology and partially antagonized the uterotropic effects of estrogen. Conclusions: These findings identify glyceollins as antiestrogenic agents that may be useful in the prevention or treatment of breast and ovarian carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=33845751547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845751547&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-1426

DO - 10.1158/1078-0432.CCR-06-1426

M3 - Article

C2 - 17145841

AN - SCOPUS:33845751547

VL - 12

SP - 7159

EP - 7164

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -